anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The objectives of the study are 1) To design and implement an e-HIV/STI testing pilot intervention (TÉSTATE PrEP) to offer self-sampling kits to detect HIV, Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Treponema pallidum (TP) among gays, bisexuals and other men who have sex with men (GBMSM) and transgender women users of pre-exposure prophylaxis (PrEP) as part of PrEP follow up. 2) To evaluate if the pilot does not cause a reduction of the retention to PrEP follow up among the target population. 3) To analyze the capacity of the intervention to reduce the healthcare burden of the PrEP service. 4) To evaluate the acceptability of the intervention among PrEP users and healthcare workers of the PrEP services; and 5) To validate dried blood samples (DBS) for confirmation of TP infection and performing RPR to determine stage and activity of infection comparing with blood drawn by venous puncture. Investigators will perform a non-blinded randomized controlled non-inferiority trial among PrEP users on follow up in one of the main PrEP services of Spain. Participants on the control arm will follow the usual follow up protocol with quarterly face-to-face visits where they will be tested for HIV and STIs. Participants in the experimental arm will alternate face-to-face meetings with online screening of HIV and STIs. This project is based on the TÉSTATE project (PI17 00355). The website https://testate.org/ will include a module for online follow-up visits of participants on PrEP. Participants of the experimental arm will register in the website and will receive self-sampling kits to their home to get tested for HIV, CT, NG and TP. Participants will send the samples to the reference laboratory and check their results online. The investigators will compare the retention to follow up among PrEP users in the control and experimental arm and the healthcare burden in each group. The acceptability of the intervention among the PrEP users and healthcare workers will be assessed.
Objective: To evaluate the effects of re-tucking the superior oblique muscle on recurrent or residual compensatory head position. Methods: A retrospective case series study was conducted. 12 recurrent or residual compensatory head position patients (12 eyes) with congenital superior oblique palsy who underwent superior oblique re-tucking in Tianjin Eye Hospital from March 2015 to February 2021 were included. All patients had a history of superior oblique tucking procedure and showed signs of superior oblique muscle palsy without inferior oblique muscle overaction. During surgery, the Guyton forced duction test is used to evaluate the relaxation of the superior oblique muscle tendon, which affects the re-tucking length of the muscle.Their head position, vertical deviation, eye movement, fovea-disa angle, and Bielschowsky head tilt test were assessed pre-and post-surgery. Statistical analysis was performed using ttest and paired samples Wilcoxon signed rank test. Results: Out of the 12 patients, 8 were male and 4 were female, aged between 2 and 9 years. The initial surgery was done at age 6, with a superior oblique recession length of (7.17±1.03) mm. Recurrent head tilt occurred in 11 patients after (3.82±0.98) months postoperatively, and 1 patient had residual head tilt, with a followup period of six months or more. Ocular motility examination revealed underaction of the superior oblique muscle, positive Bielschowsky's head tilt test, and Guyton forced duction tese indicating relaxation of the paralyzed superior oblique muscle tendon. Scar adhesion was observed at the stop of the superior oblique muscle, as well as the previous sutures. The scar and the sutures around the stop of the superior oblique muscle were released, the mean re-tucking amount was(7.83±1.59)mm. Follow-up at 12 to 18 months postoperatively showed disappearance of compensatory head position, significant improvement in superior oblique muscle lag, normal ocular motility, and no occurrence of Brown syndrome. The results of Bielschowsky head tilt were negative in 9 cases and still positive in 3 cases after superior oblique re-tucking. The primary vertical deviation was 2.5 (2.0, 5.3) prism diopter pre-operatively and 1 (0, 1) prism diopter post-operatively, respectively. The difference was statistically significant (U=6.00, P<0.001). The total amount of FDA in both eyes was (-22.04±5.47)° and (-15.27±6.08)° pre-and post-operatively, respectively. The difference was statistically significant (t=2.87, P=0.009). All 12 patients have normal eye movement after superior oblique re-tucking procedure. All patients had no compensatory head position at last follow-up. Conclusions: Superior oblique re-tucking is suitable for patients with relaxation of the superior oblique muscle tendon and extrocular rotation as the main sign. It can effectively and safely correct the recurrent or residual compensatory head position after re-tucking the superior oblique muscle.
This research investigates the outcomes of dance movement therapy (DMT) groups in the treatment of adults with depression. In total, 157 participants were involved. Of them, 109 were randomized into DMT group (n = 52) or control group (n = 57). The rest of the participants participated in non-randomized DMT groups. All participants met the criteria for the eligibility for rehabilitation psychotherapy, had depression diagnosed by a doctor, and the severity of depression threatened the ability to work/ study. All participants received treatment as usual during the research. DMT-intervention was facilitated by a dance movement therapist and included 20 x 75 mins sessions within 10 weeks. Depressive symptoms (BDI), physical and psychological distress (CORE-OM, SCL-90), ability to work/study, and body image were assessed at three measurement points: pre-measurement at the baseline, post-measurement 10 weeks after the pre-treatment measurement, and a follow-up measurement three months after the post-treatment measurement.

This research includes a larger number of participants (N = 109) than have been involved in previous studies utilising randomised controlled trials in research designs. The research generates further information about the effectiveness of dance movement therapy groups in the rehabilitation of depression as it was conducted in five cities across Finland. This type of multi-centre research can provide a realistic picture of the typical practice of a range of dance movement therapists working with participants in various geographic locations.
FIELD: medicine. SUBSTANCE: composition has biologically active ingredient produced from vegetable raw material, acidic and alkaline ingredients. At least one medicinal plant extract is used as the biologically active ingredient. The composition additionally has mixture of sodium benzoate with polyethylene glycol having molecular weight from 1500 to 6000 taken in 1: 9-9: 1 proportions and some additional substances with known contents of the ingredients. EFFECT: enhanced effectiveness of active ingredient assimilation. 3 cl
<P>PROBLEM TO BE SOLVED: To provide a low-toxic formulation of long stability and high efficacy, slight in the side effects of an aminoglycoside as an antibiotic effective for treating infectious diseases.  <P>SOLUTION: This formulation for inhibiting bacterial proliferation applies a liposomal aminoglycoside that comprises a neutral lipid, a negatively charged lipids and a sterol. The formulation contains unilamellar vesicles having an average size below 100 nm. A method for preparing liposomes containing an aminoglycoside is provided where the hydration temperature is significantly below the transition temperature of the formulation. This formulation is effectively used for the treatment of drug-susceptible and drug-resistant bacteria.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
An anaesthetic preparation comprises a soluble barbiturate salt and a soluble salt of a b ,b -disubstituted glutarimide of general formula <FORM:0829355/VI/1> wherein R1 and R2 are lower alkyl groups containing up to 6 carbon atoms and which may be joined to form an alicyclic ring, and X is a metal chosen from Group I or II of Mendelief's Periodic Table.  The barbiturate and glutarimide are present preferably as their salts with alkali metals especially sodium. The glutarimide may be present in amounts of between 10 and 50% by weight of that of the barbiturate.  The preparation may be in the form of a dry powder which gives an injectable solution when, for example, sterile water is added, or it may be in the form of an injectable solution which may also contain propylene glycol and also one or both of dimethyl formamide and diethylacetamide.  The barbiturates used may be "short" or "ultra-short" acting. Examples of barbiturates given are hexabarbitone, thiopentone, and pentobarbitone.  The substituted glutarimides are exemplified by b -ethyl-b -methyl glutarimide.  Up to 53% by weight of the glutarimide salt may be replaced in the preparation by the free imide.
UNLABELLED: Cancer patients are at risk for severe coronavirus disease 2019 (COVID-19) outcomes due to impaired immune responses. However, the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is inadequately characterized in this population. We hypothesized that cancer vs non-cancer individuals would mount less robust humoral and/or cellular vaccine-induced immune SARS-CoV-2 responses. Receptor binding domain (RBD) and SARS-CoV-2 spike protein antibody levels and T-cell responses were assessed in immunocompetent individuals with no underlying disorders (n = 479) and immunocompromised individuals (n = 115). All 594 individuals were vaccinated and of varying COVID-19 statuses (i.e., not known to have been infected, previously infected, or "Long-COVID"). Among immunocompromised individuals, 59% (n = 68) had an underlying hematologic malignancy; of those, 46% (n = 31) of individuals received cancer treatment <30 days prior to study blood collection. Ninety-eight percentage (n = 469) of immunocompetent and 81% (n = 93) of immunocompromised individuals had elevated RBD antibody titers (>1,000 U/mL), and of these, 60% (n = 281) and 44% (n = 41), respectively, also had elevated T-cell responses. Composite T-cell responses were higher in individuals previously infected with SARS-CoV-2 or those diagnosed with Long-COVID compared to uninfected individuals. T-cell responses varied between immunocompetent vs carcinoma (n = 12) cohorts (P < 0.01) but not in immunocompetent vs hematologic malignancy cohorts. Most SARS-CoV-2 vaccinated individuals mounted robust cellular and/or humoral responses, though higher immunogenicity was observed among the immunocompetent compared to cancer populations. The study suggests B-cell targeted therapies suppress antibody responses, but not T-cell responses, to SARS-CoV-2 vaccination. Thus, vaccination continues to be an effective way to induce humoral and cellular immune responses as a likely key preventive measure against infection and/or subsequent more severe adverse outcomes.
IMPORTANCE: The study was prompted by a desire to better assess the immune status of patients among our cancer host cohort, one of the largest in the New York metropolitan region. Hackensack Meridian Health is the largest healthcare system in New Jersey and cared for more than 75,000 coronavirus disease 2019 patients in its hospitals. The John Theurer Cancer Center sees more than 35,000 new cancer patients a year and performs more than 500 hematopoietic stem cell transplants. As a result, the work was undertaken to assess the effectiveness of vaccination in inducing humoral and cellular responses within this demographic.
Premature Closure of Fetal Ductus Arteriosus

Avoid use of NSAIDs, including Piroxicam Capsules, in pregnant women at about 30 weeks gestation and later. NSAIDs, including Piroxicam Capsules, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age. 

Oligohydramnios/Neonatal Renal Impairment 

Use of NSAIDs, including Piroxicam Capsules, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required. 

If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit Piroxicam Capsules use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if Piroxicam Capsules treatment extends beyond 48 hours. Discontinue Piroxicam Capsules if oligohydramnios occurs and follow up according to clinical practice [see Use in Specific Populations (8.1)].
Approximately 600 youths between the ages of 11 and 14 and their parents will be assessed. Adolescents will be evaluated at baseline using event-related potentials, self-report, and interview-based measures. The error-related negativity will be evaluated immediately (it takes less than 5 minutes to process and score a single subjects' error-related negativity ), and adolescents with good error-related negativity data (\~90%, based on scorable error-related negativity data) will be randomly assigned to either an 8-week (i.e., 16 session) adaptive attention bias modification (N=180) or control condition (N=180) or a waitlist condition (N=180) group. Each session lasts 20 minutes, and participants will be asked to complete two 20-minute sessions per week. Participants will be assessed immediately at post, using the same measures from the baseline assessment. All participants will complete a 2-year follow-up lab visit using the same measures from the baseline assessment.
Participants will receive loading dose of eculizumab 600 mg on Days 1, 8, 15, and 22, followed by maintenance dose of 900 mg on Day 29 and every 2 weeks (Q2W) thereafter until 24 weeks. Participants may switch to receive crovalimab after 24 weeks of eculizumab treatment.
Embodiments of the present disclosure provide systems and methods for a vertical take-off and landing craft. The system provides a craft capable of a vertical take-off and landing configuration and a horizontal thrust configuration. The system may include, for example, at least a proprotor, an edgewise blade, and a body. The proprotor may be configured to tilt to achieve a horizontal thrust component. A portion of a lift surface may be configured to tilt with the proprotor. In some embodiments, the vertical take-off and/or landing craft may further comprise a tail connected to a first boom and a second boom. In some embodiments, the vertical take-off and/or landing craft may further comprise a tail attached to the body.
Cardiac surgery represents only a small fraction of all surgical procedures, but consumes a significant proportion of the stored red blood cells (RBC), with almost 50% of patients receiving a perioperative transfusion. Since RBC transfusion is associated with an increased risk of morbidity and mortality, blood patient management strategy has been promoted to favour prevention of anaemia, reduction of bleeding and limitation of transfusion. Current guidelines recommend haemoglobin (Hb) threshold as low as 7 g/dL, but still with a wide possible range (7 to 9 g/dl) and suggest that Hb alone may not be the best criteria for triggering transfusion. As Hb is an oxygen carrier, the rationale for RBC transfusion should be to increase tissue oxygen delivery. Central venous oxygen saturation (central SvO2), which is related to the balance between tissue oxygen delivery and consumption, is easily measurable in cardiac surgery. In a previous study, the investigators showed that in anaemic patients having undergone cardiac surgery, restrictive transfusion according to central SvO2 allowed a significant reduction in RBC transfusion incidence in the ICU. The investigators hypothesize that a restrictive transfusion strategy adjusted by SvO2 during all the perioperative period of cardiac surgery may reduce further the incidence of RBC transfusion. Limiting RBC transfusion to patients with a low SvO2 could save unnecessary transfusions, without increasing the anaemia related risk.
Left bundle branch area pacing is an innovative technique employed to maintain left ventricular synchrony. However, the operator can face challenges in penetrating the lead into the septum during screwing. Two pitfalls-helix-only penetration and shallow penetration-hinder lead penetration. The research, conducted in 2 phases on patients and swine hearts, tested 2 techniques to overcome these issues. The results highlight the impact of endocardial involvement and suggest that the optimal technique involves intentionally creating an endocardial breach rather than simply unscrewing and rescrewing. This solution could facilitate the procedure by minimizing the number of attempts to reach the pacing site and thus reducing the risk of complications.
ADHD adolescents without any first or second degree-relatives with bipolar disorder. Low-risk ADHD adolescents (n=60) will receive treatment with open-label mixed amphetamine salts-extended release (MAS-XR), which is approved by the United States Food and Drug Administration (USFDA) for the treatment of ADHD and is a commonly prescribed psychostimulant medication for adolescents with ADHD.
In the active stimulation condition a constant current of active transcranial direct current stimulation (tDCS) of 2mA intensity was applied for 30 minutes,over primary motor cortex M1. The treatment was repeated every day for 10 consecutive days.
Paediatric asthma is an increasing global healthcare problem for which current treatments are not always effective. This review explores how abnormal triggering of the autonomic diving reflex might be important in explaining research findings and the real-world experience of asthma. It hypothesises that the way in which stress during pregnancy is associated with childhood asthma could be through effects on the developing nervous system. This results in increased parasympathetic responsiveness and specifically, excessive triggering of the diving reflex in response to wetting and cooling of the face and nose as occurs with upper airway infections and allergic rhinitis. In aquatic mammals the reflex importantly includes the contraction of airway smooth muscle to minimise lung volume and prevent nitrogen narcosis from diving at depth. Misfiring of this reflex in humans could result in the pathological airway narrowing that occurs in asthma. The diving reflex, and possibly also smooth muscle, is a vestigial remnant of our aquatic past. The hypothesis further suggests that classically conditioned reflex responses to neutral cues and contexts that were present at the same time as the stimuli that initially caused symptoms, become of themselves ongoing triggers of recurrent wheeze. Symptoms occurring in this way, irrespective of the presence of allergens and ongoing airway sensitisation, explain why allergen avoidance is poorly effective in alleviating wheeze and why asthma is made worse by stress. Interventions to suppress the diving reflex and to prevent reflex conditioned wheezing could result in more effective asthma management.
Miglustat Capsules, 100 mg are a glucosylceramide synthase inhibitor, which is a glucosyl transferase enzyme responsible for the first step in the synthesis of most glycosphingolipids. Miglustat is an N-alkylated imino sugar, a synthetic analog of D-glucose. 

The chemical name for miglustat is 1,5-(butylimino)-1,5-dideoxy-D-glucitol with the chemical formula C10H21NO4 and a molecular weight of 219.28. 

Miglustat is a white to off-white crystalline solid and has a bitter taste. It is highly soluble in water (>1000 mg/mL as a free base). 

Miglustat capsules are supplied in hard gelatin capsules each containing 100 mg miglustat for oral administration. Each miglustat 100 mg capsule also contains magnesium stearate. Ingredients in the capsule shell include gelatin, sodium lauryl sulfate and titanium dioxide, and the shells are printed with edible ink consisting of black iron oxide, propylene glycol, potassium hydroxide and shellac.
The present invention relates to inhibitors of GSK-3 and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors and methods of utilizing those compositions in the treatment and prevention of various disorders, such as diabetes and Alzheimer's disease. In addition, the invention relates to molecules or molecular complexes which comprise binding pockets of GSK-3² or its homologues. The invention relates to a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. The invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. The invention relates to methods of using the structure coordinates to screen for and design compounds that bind to GSK-3² protein or homologues thereof. The invention also relates to crystallizable compositions and crystals comprising GSK-3² protein or GSK-3² protein complexes.
The invention discloses application of HIP-55 in preparation of products for diagnosing and preventing myocardial ischemia-reperfusion injury. The invention provides an application of a HIP-55 protein or a substance capable of promoting the expression of the HIP-55 protein in any one of the following parts: preparing a product for protecting the heart in myocardial ischemia reperfusion injury; protect the heart in myocardial ischemia reperfusion injury. The invention discovers that the myocardial HIP-55 protein expression quantity of a mouse myocardial ischemia area is increased after ischemia-reperfusion; over-expression of HIP-55 can reduce the myocardial infarction area of mice. It was also found that overexpression of HIP-55 at the cellular level could inhibit the rate of cardiomyocyte apoptosis. According to the comprehensive research results, the HIP-55 plays a role in protecting the myocardium by inhibiting apoptosis and resisting oxidative stress in myocardial ischemia-reperfusion injury. The result of the invention shows that the HIP-55 is a new cardioprotective protein and provides a new target for clinical diagnosis, treatment and new drug development.
PURPOSE: To produce a compsn. for medical treatment or diagnosis having a regulated cloud point. CONSTITUTION: This compsn. contains nano-particles having a purified polymer surfactant adsorbed on the surfaces as a surface modifying agent and contg. a cloud point regulating agent in a combined state. In this compsn., the cloud point regulating agent exists by an amt. enough to raise the cloud point of the surface modifying agent. The surface modifying agent is preferably a purified polyalkylene oxide substd. ethylenediamine surfactant. The cloud point regulating agent is preferably polyethylene glycol. The nano-particles are produced through a process for bringing nano-particles into contact with the cloud point regulating agent under sufficient conditions including time to raise the cloud point of the surface modifying agent.